LARS1

Across TCGA pan-cancer cohorts, LARS1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LARS1 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher LARS1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LARS1 expression acts as an unfavorable survival marker.

LSCC, LUAD, and CCRCC are the cancer types where LARS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	III,IV	0.492	0.928	.002	23	view →
LUAD	DFS	Tertile	II,III,IV	0.261	0.783	<.001	19	view →
CCRCC	OS	Quartile	III,IV	0.555	0.911	.006	16	view →
PDAC	DFS	Tertile	III,IV	0.582	0.887	.030	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LARS1–LSCC (OS)

Open the LSCC breakdown →